In its second call for proposals, the University of Illinois Cancer Center-UICentre Drug Discovery Program (U2D2) is offering seed grants of up to $25,000 for one year focused on small-molecule drug discovery. U2D2 is a collaborative grant program directed at the development of new anti-cancer therapeutics.
Applications are due by Friday, July 21, at 5 p.m. (CDT) and award decisions will be made before September 30.
Details
Principal Investigators are required to be Cancer Center members and the seed grant proposal must be related to small-molecule cancer drug discovery, including an effort in one or more of these components:
- High-throughput screening and/or assay development
- Hit-to-lead medicinal chemistry optimization of an anticancer small molecule
- Lead optimization, including DMPK studies
- Target validation involving synthetic chemical probes
How to Apply
For more more information on how to apply, click here.
What’s Next
It is anticipated that several U2D2 funding opportunities will be announced in the period FY2023-2026. Future offerings may expand to additional drug discovery approaches, such as biologic or nanoparticle development